The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
about
Renal effects of dapagliflozin in patients with type 2 diabetesNew Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney DiseaseOptions for empagliflozin in combination therapy in type 2 diabetes mellitusPatient considerations in type 2 diabetes - role of combination dapagliflozin-metformin XRCanagliflozin Treatment in Patients with Type 2 Diabetes MellitusEfficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusSodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetesBeat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agentsStrategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the DiseaseSodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A ReviewImpact of sodium-glucose cotransporter 2 inhibitors on blood pressureMathematical modeling of renal tubular glucose absorption after glucose loadIsolation and characterization of a primary proximal tubular epithelial cell model from human kidney by CD10/CD13 double labelingWhy Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?Optimal therapy of type 2 diabetes: a controversial challengeMaternal blood cadmium, lead and arsenic levels, nutrient combinations, and offspring birthweight.Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy.SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patientEmpagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Empagliflozin in the treatment of type 2 diabetes: evidence to dateThe pathophysiology of hypertension in patients with obesity.Diabetes-resistant NOR mice are more severely affected by streptozotocin compared to the diabetes-prone NOD mice: correlations with liver and kidney GLUT2 expressions.Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study.Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitusSGLT-2 Inhibitors: A New Mechanism for Glycemic Control.Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis.Sodium Glucose Cotransporter 2 (SGLT2) Plays as a Physiological Glucose Sensor and Regulates Cellular Contractility in Rat Mesangial Cells.Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring.SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery.Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 DiabetesEvaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus.Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 DiabetesManagement of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of NephropathySafety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitusA novel SGLT is expressed in the human kidney.Post-glucose-load urinary C-peptide and glucose concentration obtained during OGTT do not affect oral minimal model-based plasma indices
P2860
Q24564811-05CE47B9-9060-4582-B4F0-6482E2CF69D7Q26739475-AC3C22A3-B361-4084-8A37-B4DADB886D6CQ26745771-D3E951F1-2762-4972-827D-7A85AD0D025DQ26766404-74C9ABAA-C746-4E19-9B2A-81839500D2A3Q26777529-AD36801B-4929-4263-884B-922CC96FEE0DQ26782225-1EB0EF85-D2C4-414D-A7A3-0EFA816C30B6Q26864336-A89B08FE-0E60-4E86-A5D7-1C2C59FF8E8DQ27010669-FD3CC261-8B3A-449D-AD40-523DAE701070Q28069065-1F205DD0-8453-49BD-A91A-5C672B057B94Q28079134-1277F3B3-8985-4381-986A-295F58A4FC8FQ28080114-652BA5D2-B089-4E5F-8C7A-B155A9678785Q28539294-835D94D6-17B9-41D9-827F-5D6F4ADAC44EQ31121258-872B1227-70C8-416D-9A49-9C4E59523F5DQ33354192-6256CE17-33A9-4A98-AEA3-39B6ABB4B891Q33577712-788196F7-5A04-4135-94DD-51519E14E924Q33595643-F2B95EB3-7EF0-4CE0-99E6-7B695CDE7830Q33665173-FC103F85-F3F0-4A4E-9091-C63C2A024912Q33696974-B151CD83-285B-4F6A-8B10-ED3F22D969A4Q33759570-90B54F2A-D0F3-4C60-9BA5-B3E3210D1C96Q33837017-34F51893-CB9B-4FCB-8125-5081C89EF304Q34161881-7E12BB56-F1D9-4496-BAAC-242C5EEC6A83Q34502358-905ECDC5-74C9-4840-B097-B7A26DE97E65Q35021492-72C30C76-1A2E-4F8B-821F-3AF52F36C7B2Q35074611-3BFE0599-CF84-4BFC-890D-B68651DA6CD4Q35117192-4214FBC4-8F39-4873-BFCF-1CBB303A2E36Q35192198-49944EC4-AE9E-489E-BFED-B84DF9183DE9Q35879325-6FFCA161-7F95-4396-9397-9C1909395E41Q35906490-C244BFCC-1983-4A2A-A4DF-68B70CC354FDQ35911236-7273E541-294C-473D-8E59-CE8C19B61A96Q35964702-C29378B4-53E3-4246-9204-E00F782358AEQ36232787-E2CCDBCC-9FAD-4FF9-BF68-0966DF114ABEQ36237217-7E945E47-AEFD-474E-8790-25580DE9E1A8Q36257199-3063F3F1-6A60-4833-BE8C-C8667FD3ECC2Q36257565-47B59EAD-64CE-451F-BE3B-FA71CDFB2CA6Q36333760-94C13E1B-DEE2-4F2D-A4F8-7F9FAE84B42DQ36373688-8694A77C-9D93-473D-A249-5F8795618DACQ36402095-52C7E33A-B7A5-42EA-81A2-F10D2BE6AA06Q36527897-F95B4B85-F3B3-43CD-AE08-20B447E09B77Q36706015-737F4B79-7CB1-48E8-93A7-53FAA779EAEAQ36778119-3D7978BB-4003-4B66-B77C-C6169923C881
P2860
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
@en
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
@nl
type
label
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
@en
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
@nl
prefLabel
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
@en
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
@nl
P2860
P1476
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
@en
P2093
J A Davidson
R A DeFronzo
P2860
P356
10.1111/J.1463-1326.2011.01511.X
P577
2012-01-01T00:00:00Z